US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neuphoria Therapeutics Inc

4.35

+0.08001.87%

Post-market: 4.350.00000.00%16:10 EST

Volume:46.13K

Turnover:198.72K

Market Cap:23.39M

PE:-1.08

High:4.39

Open:4.25

Low:4.21

Close:4.27

52wk High:21.40

52wk Low:3.65

Shares:5.38M

Float Shares:3.87M

Volume Ratio:1.30

T/O Rate:1.19%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0200

EPS(LYR):-0.2278

ROE:-26.07%

ROA:-4.25%

PB:0.79

PE(LYR):-19.10

Loading ...

Overview Company News Filings

Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its Business

Simply Wall St.

Neuphoria Therapeutics posts Q4 income before income taxes of USD 1.83 million, reversing a loss

Lynx1 Capital Management - on Dec 26, Offered to Acquire Neuphoria Therapeutics' Ip Assets via Cash or Equivalent Stock - SEC Filing

THOMSON REUTERS

Neuphoria Therapeutics Inc. Held Annual Shareholder Meeting

Leading Proxy Advisory Firm Iss Recommends That Shareholders Vote the White Proxy Card for Both of Neuphoria’s Director Nominees

THOMSON REUTERS

Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $7 From $21

THOMSON REUTERS

Neuphoria Therapeutics Inc - Lynx1's New Bid Lower Than Initial $4.75 per Share

THOMSON REUTERS

Neuphoria Therapeutics Inc - Pauses R&D Expenditures for Bnc210 in Ptsd & Is Evaluating All Possibilities as Part of the Co's Strategic Review

THOMSON REUTERS

Neuphoria Therapeutics Inc - Received Substantial Competing Indications of Interest

THOMSON REUTERS

Neuphoria Therapeutics Inc - Urges Stockholders to Vote "for" Both of Neuphoria's Nominees on White Proxy Card

THOMSON REUTERS

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Lynx1 Capital Management Lp Says on Dec 2, Deliveres Letter to Neuphoria Therapeutics' Board - SEC Filing

THOMSON REUTERS

Lynx1 Capital Management - Letter to Neuphoria Therapeutics Contains Non-Binding Proposal to Buy Co's Outstanding Shares for $4.75/Share in Cash

THOMSON REUTERS

Press Release: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics: Strategic Review Process Is Well Underway

THOMSON REUTERS

Neuphoria Therapeutics Faces Proxy Battle as Dissident Investor Nominates Rival Directors

Lynx1 Capital Management Lp - Withdraws Previous Non-Binding Proposal to Acquire Neuphoria Therapeutics - SEC Filing

THOMSON REUTERS

BRIEF-Neuphoria Therapeutics May Offer & Sell Common Stock Of Up To $20 Million From Time To Time - SEC Filing

Neuphoria Therapeutics Inc - May Offer & Sell Common Stock of up to $20 Mln From Time to Time - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NEUP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEUP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEUP\",,,,,undefined,":{"symbol":"NEUP","market":"US","secType":"STK","nameCN":"Neuphoria Therapeutics Inc","latestPrice":4.35,"timestamp":1771621200000,"preClose":4.27,"halted":0,"volume":46132,"hourTrading":{"tag":"盘后","latestPrice":4.35,"preClose":4.35,"latestTime":"16:10 EST","volume":2,"amount":8.58,"timestamp":1771621804568,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.018735362997658097,"floatShares":3867799,"shares":5377329,"eps":-4.02,"marketStatus":"Market Closed","change":0.08,"latestTime":"02-20 16:00:00 EST","open":4.25,"high":4.39,"low":4.2095,"amount":198724.2116,"amplitude":0.042272,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.02,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":4.27,"preHourTrading":{"tag":"盘前","latestPrice":4.29,"preClose":4.29,"latestTime":"09:08 EST","volume":171,"amount":733.7499705,"timestamp":1771596495205,"change":0,"changeRate":0,"amplitude":0.037296},"postHourTrading":{"tag":"盘后","latestPrice":4.35,"preClose":4.35,"latestTime":"16:10 EST","volume":2,"amount":8.58,"timestamp":1771621804568,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.304040571491625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEUP\",,,,,undefined,":{"symbol":"NEUP","floatShares":3867799,"roa":"-4.25%","roe":"-26.07%","lyrEps":-0.227756,"volumeRatio":1.304040571491625,"shares":5377329,"dividePrice":0,"high":4.39,"amplitude":0.042272,"preClose":4.27,"low":4.2095,"week52Low":3.645,"pbRate":"0.79","psRate":"1.56","week52High":21.4004,"institutionHeld":0.111,"latestPrice":4.35,"eps":-4.02,"divideRate":0,"volume":46132,"delay":0,"ttmEps":-4.02,"open":4.25,"prevYearClose":3.88,"prevWeekClose":4.05,"prevMonthClose":4.02,"prevQuarterClose":3.88,"fiveDayClose":4.07,"twentyDayClose":4.17,"sixtyDayClose":4.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEUP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-17","symbol":"NEUP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1771304400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2025-11-14","symbol":"NEUP","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-4.41},{"market":"US","date":"2025-09-29","symbol":"NEUP","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1759118400000,"reportTimeType":"post","actualEps":-5.79},{"market":"US","date":"2024-12-24","symbol":"NEUP","defaultRemindTime":1735050600000,"type":"split","dateTimestamp":1735016400000,"forFactor":12,"toFactor":1,"ratio":12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEUP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NEUP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1761022800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NEUP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NEUP","date":"2026-02-20","current":-1.08209,"percent":0.149826,"low":-2152.911097,"twenty":-2.390214,"median":-1.079248,"eighty":2.308737,"high":4.870093,"avg":-35.972426,"sd":202.374122,"marketCap":23019121},"quantilePoints":[{"date":"2024-12-27","current":-1445.015744,"twenty":-2011.332026,"median":-1798.963421,"eighty":-1586.594815,"marketCap":15641406744},{"date":"2025-01-03","current":-951.437333,"twenty":-1445.015744,"median":-1245.311321,"eighty":-1113.798652,"marketCap":10298723991},{"date":"2025-01-10","current":-0.484092,"twenty":-1335.908938,"median":-1032.617992,"eighty":-0.531583,"marketCap":5240001},{"date":"2025-01-17","current":-0.452507,"twenty":-1207.318772,"median":-0.536694,"eighty":-0.48107,"marketCap":4898109},{"date":"2025-01-24","current":-0.524667,"twenty":-1141.075354,"median":-0.511137,"eighty":-0.48107,"marketCap":5679203},{"date":"2025-01-31","current":-0.81331,"twenty":-1016.381861,"median":-0.554735,"eighty":-0.482883,"marketCap":8803579},{"date":"2025-02-07","current":-0.757686,"twenty":-381.062919,"median":-0.702062,"eighty":-0.484985,"marketCap":8201486},{"date":"2025-02-14","current":-0.691539,"twenty":-0.803388,"median":-0.699056,"eighty":-0.486483,"marketCap":7485483},{"date":"2025-02-21","current":-1.080318,"twenty":-1.103422,"median":-0.706573,"eighty":-0.495533,"marketCap":8872986},{"date":"2025-02-28","current":-1.110267,"twenty":-1.105989,"median":-0.757686,"eighty":-0.509378,"marketCap":9118970},{"date":"2025-03-07","current":-1.180862,"twenty":-1.111551,"median":-0.770464,"eighty":-0.516549,"marketCap":9698789},{"date":"2025-03-14","current":-1.035394,"twenty":-1.111551,"median":-0.796773,"eighty":-0.529478,"marketCap":8504010},{"date":"2025-03-21","current":-1.108128,"twenty":-1.110267,"median":-1.022558,"eighty":-0.551126,"marketCap":9101399},{"date":"2025-03-28","current":-1.240761,"twenty":-1.1415,"median":-1.048229,"eighty":-0.607653,"marketCap":10190756},{"date":"2025-04-04","current":-1.210812,"twenty":-1.180862,"median":-1.055716,"eighty":-0.664779,"marketCap":9944772},{"date":"2025-04-11","current":-1.048229,"twenty":-1.179151,"median":-1.052508,"eighty":-0.679813,"marketCap":8609432},{"date":"2025-04-17","current":-1.093153,"twenty":-1.172305,"median":-1.056786,"eighty":-0.692441,"marketCap":8978407},{"date":"2025-04-25","current":-1.110267,"twenty":-1.154335,"median":-1.064274,"eighty":-0.697252,"marketCap":9118970},{"date":"2025-05-02","current":-1.069622,"twenty":-1.152624,"median":-1.071761,"eighty":-0.702663,"marketCap":8785135},{"date":"2025-05-09","current":-1.056786,"twenty":-1.146207,"median":-1.070692,"eighty":-0.70567,"marketCap":8679713},{"date":"2025-05-16","current":-1.014001,"twenty":-1.12567,"median":-1.069622,"eighty":-0.714089,"marketCap":8328307},{"date":"2025-05-23","current":1.878545,"twenty":-1.12567,"median":-1.066199,"eighty":-0.70567,"marketCap":10946278},{"date":"2025-05-30","current":2.090639,"twenty":-1.118824,"median":-1.058925,"eighty":-0.691539,"marketCap":12182153},{"date":"2025-06-06","current":2.306801,"twenty":-1.112407,"median":-1.056786,"eighty":-0.536694,"marketCap":13441728},{"date":"2025-06-13","current":2.303575,"twenty":-1.112407,"median":-1.053577,"eighty":-0.487084,"marketCap":13422928},{"date":"2025-06-20","current":2.135807,"twenty":-1.112407,"median":-1.052016,"eighty":-0.48107,"marketCap":12445348},{"date":"2025-06-27","current":2.193881,"twenty":-1.110695,"median":-1.048229,"eighty":-0.028511,"marketCap":12783741},{"date":"2025-07-03","current":2.300349,"twenty":-1.110267,"median":-1.04609,"eighty":1.971267,"marketCap":13404129},{"date":"2025-07-11","current":2.451984,"twenty":-1.110267,"median":-1.029511,"eighty":2.139033,"marketCap":14287711},{"date":"2025-07-18","current":2.416495,"twenty":-1.110267,"median":-1.009723,"eighty":2.183557,"marketCap":14080915},{"date":"2025-07-25","current":2.710088,"twenty":-1.108984,"median":-0.902959,"eighty":2.199559,"marketCap":15791680},{"date":"2025-08-01","current":2.616525,"twenty":-1.108128,"median":-0.783243,"eighty":2.258407,"marketCap":15246491},{"date":"2025-08-08","current":2.500379,"twenty":-1.107461,"median":-0.765954,"eighty":2.294542,"marketCap":14569705},{"date":"2025-08-15","current":2.613299,"twenty":-1.106066,"median":-0.738143,"eighty":2.306801,"marketCap":15227692},{"date":"2025-08-22","current":2.232596,"twenty":-1.104483,"median":-0.703565,"eighty":2.308091,"marketCap":13009337},{"date":"2025-08-29","current":3.939307,"twenty":-1.101283,"median":-0.691539,"eighty":2.322933,"marketCap":22954336},{"date":"2025-09-05","current":3.845744,"twenty":-1.099571,"median":-0.659969,"eighty":2.388052,"marketCap":22409147},{"date":"2025-09-12","current":4.513587,"twenty":-1.099503,"median":-0.53068,"eighty":2.412623,"marketCap":26300668},{"date":"2025-09-19","current":3.032718,"twenty":-1.096901,"median":-0.508206,"eighty":2.459921,"marketCap":17671642},{"date":"2025-09-26","current":4.016738,"twenty":-1.093153,"median":-0.484837,"eighty":2.484247,"marketCap":23405526},{"date":"2025-10-03","current":-93.377884,"twenty":-1.099571,"median":-0.487084,"eighty":2.484247,"marketCap":34515454},{"date":"2025-10-10","current":-121.187146,"twenty":-1.107683,"median":-0.517902,"eighty":2.484247,"marketCap":44794647},{"date":"2025-10-17","current":-96.758368,"twenty":-1.110267,"median":-0.572775,"eighty":2.482957,"marketCap":35764989},{"date":"2025-10-24","current":-25.831995,"twenty":-1.112407,"median":-0.681767,"eighty":2.474697,"marketCap":9548332},{"date":"2025-10-31","current":-28.064391,"twenty":-1.152196,"median":-0.702062,"eighty":2.459921,"marketCap":10373497},{"date":"2025-11-07","current":-27.298997,"twenty":-1.179151,"median":-0.72311,"eighty":2.450694,"marketCap":10090583},{"date":"2025-11-14","current":-30.296784,"twenty":-1.215946,"median":-0.765203,"eighty":2.444886,"marketCap":11198661},{"date":"2025-11-21","current":-2.390214,"twenty":-1.237338,"median":-0.778733,"eighty":2.430045,"marketCap":22638555},{"date":"2025-11-28","current":-2.566216,"twenty":-2.485596,"median":-0.805041,"eighty":2.414559,"marketCap":24305527},{"date":"2025-12-05","current":-2.424279,"twenty":-2.506035,"median":-0.994748,"eighty":2.406545,"marketCap":22961194},{"date":"2025-12-12","current":-2.259633,"twenty":-2.513983,"median":-1.018814,"eighty":2.405087,"marketCap":21401769},{"date":"2025-12-19","current":-2.208535,"twenty":-2.506035,"median":-1.043951,"eighty":2.402299,"marketCap":20917809},{"date":"2025-12-26","current":-2.151761,"twenty":-2.492409,"median":-1.048229,"eighty":2.397137,"marketCap":20380076},{"date":"2026-01-02","current":-2.202858,"twenty":-2.483325,"median":-1.048229,"eighty":2.378967,"marketCap":20864036},{"date":"2026-01-09","current":-2.31073,"twenty":-2.435634,"median":-1.052508,"eighty":2.369366,"marketCap":21885729},{"date":"2026-01-16","current":-2.327762,"twenty":-2.424279,"median":-1.055289,"eighty":2.331967,"marketCap":22047048},{"date":"2026-01-23","current":-2.367504,"twenty":-2.40384,"median":-1.056786,"eighty":2.322933,"marketCap":22423461},{"date":"2026-01-30","current":-2.282342,"twenty":-2.390214,"median":-1.06192,"eighty":2.319061,"marketCap":21616862},{"date":"2026-02-06","current":-2.268149,"twenty":-2.386808,"median":-1.069622,"eighty":2.31648,"marketCap":21482429},{"date":"2026-02-13","current":-2.31073,"twenty":-2.38113,"median":-1.071761,"eighty":2.312608,"marketCap":21885729},{"date":"2026-02-20","current":-4.064176,"twenty":-2.390214,"median":-1.079248,"eighty":2.308737,"marketCap":23019121}],"updateTime":1771736518161},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEUP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612406239","title":"Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2612406239","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612406239?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:18","pubTimestamp":1771496304,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-neup/neuphoria-therapeutics/news/neuphoria-therapeutics-nasdaqneup-is-in-a-strong-position-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-neup/neuphoria-therapeutics/news/neuphoria-therapeutics-nasdaqneup-is-in-a-strong-position-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USJW.SI","GPIQ","JEPQ","NVIW.SI","QQQY","TSYW.SI","QLD","QQQE","NEUP","USAW.SI","BK4139","PSQ","QYLD","QYLG","MNQmain","TQQQ","SQQQ","QID",".IXIC","NQmain","QQQJ"],"gpt_icon":1},{"id":"2612746728","title":"Neuphoria Therapeutics posts Q4 income before income taxes of USD 1.83 million, reversing a loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2612746728","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612746728?lang=en_us&edition=fundamental","pubTime":"2026-02-18 04:58","pubTimestamp":1771361908,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc. reported income before income taxes of USD 1.83 million for the quarter ended December 31, 2025, compared to a loss in the prior-year period. Revenue declined during the quarter, mainly due to the absence of a milestone payment received in the previous year from a licensing agreement with Carina Biotech Pty Ltd. Research and development expenses decreased by USD 1.0 million, reflecting reduced contract-related costs, lower professional fees, and decreased headcount as the company paused development activities while seeking a strategic merger partner. General and administrative expenses also fell by USD 0.5 million, primarily due to headcount reductions. As part of a restructuring initiative, Neuphoria terminated its facility leases and substantially all employees, resulting in employee termination costs of approximately USD 1.4 million and other restructuring costs of around USD 0.4 million for the quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL5BM5cb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2595539337","title":"Lynx1 Capital Management - on Dec 26, Offered to Acquire Neuphoria Therapeutics' Ip Assets via Cash or Equivalent Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595539337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595539337?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:40","pubTimestamp":1767044408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XY084:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2592943685","title":"Neuphoria Therapeutics Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943685?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:02","pubTimestamp":1766005329,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc. held its Annual Meeting of Shareholders on December 12, 2025. At the meeting, shareholders elected Peter Miles Davies and David Wilson as Class I directors to the board. The appointment of Wolf & Company P.C. as the independent registered public accounting firm for the fiscal year ending June 30, 2026, was also ratified. Nominees Stephen Doberstein and Kimberly Smith were not elected to the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuphoria Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsibl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL42HwYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2589935366","title":"Leading Proxy Advisory Firm Iss Recommends That Shareholders Vote the White Proxy Card for Both of Neuphoria’s Director Nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2589935366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589935366?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199124,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2589533213","title":"Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533213?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198800,"startTime":"0","endTime":"0","summary":"Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card. \"We are very pleased that ISS has carefully reviewed the voting alternatives and has recommended that shareholders vote FOR BOTH of Neuphoria's highly-qualified director nominees on the WHITE proxy card. We are also pleased that in making its recommendation, ISS recognized that the Board has acted appropriately and proactively in connection with the data readout from the Phase 3 clinical trial of BNC210 and ongoing capital raise. We believe that the strategic alternatives process that the Board is running needs to be seen to fruition and has the best opportunity to provide shareholders with maximum value. We strongly urge all shareholders to follow the recommendation of ISS and vote TODAY on the WHITE proxy card FOR BOTH of Neuphoria's director nominees to ensure that Neuphoria is best positioned to execute on its strategic alternatives process in order to provide shareholders with maximum value.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4024","NEUP","FOR"],"gpt_icon":0},{"id":"2589892326","title":"Neuphoria Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $7 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892326?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:34","pubTimestamp":1764938081,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nAZN4RB1VX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2588884408","title":"Neuphoria Therapeutics Inc - Lynx1's New Bid Lower Than Initial $4.75 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884408?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853250,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2588844058","title":"Neuphoria Therapeutics Inc - Pauses R&D Expenditures for Bnc210 in Ptsd & Is Evaluating All Possibilities as Part of the Co's Strategic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2588844058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588844058?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853250,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02J:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2588842898","title":"Neuphoria Therapeutics Inc - Received Substantial Competing Indications of Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2588842898","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588842898?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853250,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2588842118","title":"Neuphoria Therapeutics Inc - Urges Stockholders to Vote \"for\" Both of Neuphoria's Nominees on White Proxy Card","url":"https://stock-news.laohu8.com/highlight/detail?id=2588842118","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588842118?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853250,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02J:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2588388284","title":"Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588388284","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588388284?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853200,"startTime":"0","endTime":"0","summary":"Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTHof Neuphoria’s Nominees on theWHITEProxy C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199742/0/en/Neuphoria-Responds-to-Lynx1-s-Revised-Indication-of-Interest-at-a-Reduced-Price-and-Premium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2588305521","title":"Lynx1 Capital Management Lp Says on Dec 2, Deliveres Letter to Neuphoria Therapeutics' Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588305521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588305521?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:31","pubTimestamp":1764682298,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2588055249","title":"Lynx1 Capital Management - Letter to Neuphoria Therapeutics Contains Non-Binding Proposal to Buy Co's Outstanding Shares for $4.75/Share in Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055249?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:31","pubTimestamp":1764682298,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80LH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2588072039","title":"Press Release: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions","url":"https://stock-news.laohu8.com/highlight/detail?id=2588072039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588072039?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:01","pubTimestamp":1764594060,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass., Dec. 01, 2025  -- Neuphoria Therapeutics Inc.  , a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP  full of deception and distraction to deflect attention from its own limitations and its handpicked nominees' shortcomings.The Company urges stockholders to trust Neuphoria's commitment to transparency and value creation over what it believes are Lynx1's fabrications and misdirection by voting FOR Neuphoria's nominees Peter Miles Davies and David Wilson on the WHITE proxy card and voting WITHHOLD on both of Lynx1's nominees.Included below are examples of quotes and assertions by Lynx1 that Neuphoria strongly believes are false and misleading, which are set against Neuphoria's explanation of the true facts.In a desperate attempt to divert stock","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2585462635","title":"Neuphoria Therapeutics: Strategic Review Process Is Well Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462635?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:03","pubTimestamp":1763989384,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00JM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2585626114","title":"Neuphoria Therapeutics Faces Proxy Battle as Dissident Investor Nominates Rival Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2585626114","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585626114?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989218,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc., a clinical-stage biotechnology company, is experiencing shareholder activism ahead of its 2025 Annual Meeting of Stockholders, scheduled for December 12, 2025. A dissident stockholder, Lynx1 Master Fund LP, has nominated two candidates for election to the Board of Directors, challenging the company's slate. Neuphoria is urging stockholders to vote \"FOR\" its two nominees, Peter Miles Davies and David Wilson, and to \"WITHHOLD\" votes from Lynx1's nominees. The company states that its Board is conducting a comprehensive review of strategic alternatives, with guidance from financial advisor H.C. Wainwright & Co., aiming to maximize value for all stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neupho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4MBFSm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","NEUP","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD","BK4585","BK4588","LU2210149790.SGD","NDAQ","BK4112"],"gpt_icon":0},{"id":"2584045930","title":"Lynx1 Capital Management Lp - Withdraws Previous Non-Binding Proposal to Acquire Neuphoria Therapeutics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584045930","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584045930?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:37","pubTimestamp":1763473062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2583684171","title":"BRIEF-Neuphoria Therapeutics May Offer & Sell Common Stock Of Up To $20 Million From Time To Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684171","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684171?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:25","pubTimestamp":1763155557,"startTime":"0","endTime":"0","summary":"BRIEF-Neuphoria Therapeutics May Offer & Sell Common Stock Of Up To $20 Million From Time To Time - SEC FilingNov 14  - Neuphoria Therapeutics Inc NEUP.O:NEUPHORIA THERAPEUTICS INC - MAY OFFER & SELL COMMON STOCK OF UP TO $20 MILLION FROM TIME TO TIME - SEC FILINGSource text: [ID:n0001213900-25-110865]Further company coverage: NEUP.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2583684130","title":"Neuphoria Therapeutics Inc - May Offer & Sell Common Stock of up to $20 Mln From Time to Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684130?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:24","pubTimestamp":1763155497,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}]}}